Thesis
Dual-approved PK activator seeks sickle cell label under accelerated approval, contingent on FDA accepting single-arm RISE UP data as the regulatory basis
Mitapivat already holds approved thalassemia labels in the U.S. and Europe, generating $44.7M in Q2 2026 revenue, and now targets sickle cell disease under accelerated approval with a November 2026 PDUFA date. The thesis turns on whether FDA grants approval on the RISE UP data and whether REIGNITE confirms clinical benefit before any post-market withdrawal risk materializes. The accelerated approval pathway itself is the primary structural risk: single-arm or surrogate-endpoint data could face regulatory skepticism, and tebapivat's dual Phase 2 failures remove a key pipeline buffer.
Focus
Mitapivat sNDA submission for sickle cell disease
November 1, 2026
Bull
FDA grants accelerated approval for mitapivat in sickle cell disease on or before the PDUFA date, validating the RISE UP single-arm dataset as adequate evidence of effect on a surrogate or intermediate endpoint. This would open a large, underserved patient population to a commercially available oral PK activator, meaningfully expanding the addressable market beyond thalassemia and driving a step-change in revenue trajectory alongside the ongoing REIGNITE confirmatory trial.
Bear
FDA issues a Complete Response Letter on the grounds that single-arm RISE UP data are insufficient to establish a reasonably likely surrogate endpoint or that the magnitude of hemoglobin response does not meet the bar for accelerated approval in sickle cell disease. A second failure mode is an advisory committee raising safety or efficacy concerns specific to the sickle cell population that differ from the thalassemia experience, or FDA requesting additional data before granting any form of approval.
Unlock the full thesis for AGIO.
The living thesis log, full pipeline, competitive landscape, and the ability to ask anything — updated automatically as the story changes.
Start your 7-day free trialRelated companies
Generated automatically from SEC filings, trial readouts, and earnings calls. For informational purposes only. Not financial advice.